|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
gptkb:physician
standard lupus therapy
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AA26
|
|
gptkbp:brand
|
gptkb:Benlysta
|
|
gptkbp:CASNumber
|
356547-88-1
|
|
gptkbp:contraindication
|
hypersensitivity to belimumab
|
|
gptkbp:developedBy
|
gptkb:Human_Genome_Sciences
GlaxoSmithKline
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:form
|
lyophilized powder
pre-filled syringe
auto-injector
|
|
gptkbp:halfLife
|
19 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
belimumab
|
|
gptkbp:indication
|
autoimmune diseases
|
|
gptkbp:isMonoclonalAntibodyType
|
IgG1-lambda
|
|
gptkbp:KEGGID
|
D08913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits B-lymphocyte stimulator (BLyS)
|
|
gptkbp:molecularWeight
|
147 kDa
|
|
gptkbp:monoclonalAntibodySource
|
u (human)
|
|
gptkbp:notRecommendedFor
|
severe active central nervous system lupus
severe active lupus nephritis (prior to 2020)
|
|
gptkbp:origin
|
human monoclonal antibody
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescribes
|
adults
children aged 5 and older
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1743027
DB08879
24873459
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
fever
nausea
diarrhea
infections
infusion reactions
|
|
gptkbp:target
|
gptkb:BLyS
|
|
gptkbp:UNII
|
4ZB7MPF6BR
|
|
gptkbp:usedFor
|
gptkb:systemic_lupus_erythematosus
lupus nephritis
|
|
gptkbp:bfsParent
|
gptkb:BAFF
|
|
gptkbp:bfsLayer
|
7
|